Nanovaccine for Eliciting Broadly Neutralizing Antibodies against HIV-1

Award Notice Posted

Solicitation number
75N93024C00019
Agency
Awarded
to Neovaxsyn Inc.
Set-aside
Total Small Business

Opportunity facts

Contract number
75N93024C00019 Federal contract award
Place of performance
Ames, Iowa 50014, United States

Notice details come from SAM.gov. Updated .

About this opportunity

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, has awarded contract 75N93024C00019 to NeoVaxSyn Inc. for a nanovaccine research project targeting HIV-1. The contract, valued at $2,000,000, will support research focused on developing a vaccine capable of eliciting broadly neutralizing antibodies against HIV-1. The period of performance spans from July 1, 2024, through June 30, 2027, with work to be conducted at NeoVaxSyn's facility in Ames, Iowa. The contract was set aside for small businesses and falls under the NAICS code 541715 for research and development in physical, engineering, and life sciences.

Notice text

Awarded contract 75N93024C00019 to NEOVAXSYN INC for 2000000.00 on 2024-06-25.

Files

File Type Posted
Award Synopsis NeoVaxSyn.pdf PDF

Notice history

Notice Type Posted
This notice Latest Award Notice
Nanovaccine for Eliciting Broadly Neutralizing Antibodies against HIV-1 Original Award Notice

Similar open opportunities

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors